Over the past few years, the CRO Novotech has cemented its position in the Asia-Pacific region, but its latest move will see it planting its flag on two different continents.
On Monday, Novotech announced it has acquired two CROs: the Colorado-based CBR International and the Poland-based eastHORN.
CBR is a consultancy company focused on guiding pharma companies through FDA requirements and offers services that include regulatory strategy, FDA representation and scientific affairs to support cGMP requirements, among others. The acquisition will now allow Novotech to add US and global regulatory, quality and development services to its arsenal. This includes assisting with submissions such as IND, BLA, fast track and orphan drug applications.
The acquisition of eastHORN gives Novotech a toehold in the European market, allowing Novotech’s clients the ability to access that continent’s markets for wider drug development.
However, the financial details…
Click here to view original post